
Contents
-
-
-
-
-
-
-
-
-
5.1 Introduction 5.1 Introduction
-
5.2 Precision Medicines and the Drug Development Process 5.2 Precision Medicines and the Drug Development Process
-
5.2.1 Precision Medicines and Biomarkers 5.2.1 Precision Medicines and Biomarkers
-
5.2.2 The Drug Development Pipeline 5.2.2 The Drug Development Pipeline
-
5.2.3 The Role of Major Pharmaceutical R&D Actors 5.2.3 The Role of Major Pharmaceutical R&D Actors
-
-
5.3 The Economics of Precision Medicine 5.3 The Economics of Precision Medicine
-
5.4 Data 5.4 Data
-
5.4.1 Data Composition and Summary Statistics 5.4.1 Data Composition and Summary Statistics
-
5.4.2 Biomarker Data and Defining Pipeline Precision Medicines 5.4.2 Biomarker Data and Defining Pipeline Precision Medicines
-
-
5.5 Characterizing the LPM Development Pipeline 5.5 Characterizing the LPM Development Pipeline
-
5.5.1 Biomarkers and LPMs in Clinical Trials 5.5.1 Biomarkers and LPMs in Clinical Trials
-
5.5.2 Pipeline Precision Cancer Therapies 5.5.2 Pipeline Precision Cancer Therapies
-
5.5.3 Institutional Factors 5.5.3 Institutional Factors
-
-
5.6 Conclusion 5.6 Conclusion
-
Appendix Appendix
-
References References
-
-
-
-
-
-
-
-
-
5 Characterizing the Drug Development Pipeline for Precision Medicines
Get access-
Published:April 2019
Cite
Abstract
Precision medicines—therapies that rely on the use of genetic, epigenetic, and protein biomarkers—create a better match between patients with specific disease subtypes and medications that are more effective for those patients. This heterogeneity in response has implications for the decision to develop therapies, their pricing, the design of clinical trials, and the relative importance of smaller biotech companies versus more traditional companies in pursuing early-stage R&D. To understand the scope of these effects, we use a comprehensive database of over 130,000 global clinical trials and describe the drug development pipeline for precision medicines over the past two decades. We identify clinical trials for likely precision medicines (LPMs) as those that use one or more relevant biomarkers. We then further segment trials based on the nature of the biomarker(s) used and other trial features with economic implications. Since cancers represent a disease setting in which precision therapies are already successfully used, and since cancer applications of precision medicine are expected to grow rapidly over the coming years, we separately characterize cancer LPMs. Finally, we consider the types of firms pursuing R&D in precision medicines, considering how LPM R&D activities have evolved over recent years.
Sign in
Personal account
- Sign in with email/username & password
- Get email alerts
- Save searches
- Purchase content
- Activate your purchase/trial code
- Add your ORCID iD
Purchase
Our books are available by subscription or purchase to libraries and institutions.
Purchasing informationMonth: | Total Views: |
---|---|
August 2024 | 1 |
Get help with access
Institutional access
Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:
IP based access
Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.
Sign in through your institution
Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.
If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.
Sign in with a library card
Enter your library card number to sign in. If you cannot sign in, please contact your librarian.
Society Members
Society member access to a journal is achieved in one of the following ways:
Sign in through society site
Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:
If you do not have a society account or have forgotten your username or password, please contact your society.
Sign in using a personal account
Some societies use Oxford Academic personal accounts to provide access to their members. See below.
Personal account
A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.
Some societies use Oxford Academic personal accounts to provide access to their members.
Viewing your signed in accounts
Click the account icon in the top right to:
Signed in but can't access content
Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.
Institutional account management
For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.